CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein

American Journal of Pathology

Volumn 174, Issue 6, 2009, Pages 2061-2072

  Gutwein, Paul ^a   Abdel Bakky, Mohamed Sadek ^a   Schramme, Anja ^b   Doberstein, Kai ^a   Kämpfer Kolb, Nicole ^a   Amann, Kerstin ^c   Hauser, Ingeborg A ^d   Obermüller, Nicholas ^d   Bartel, Christine ^d   Abdel Aziz, Abdel Aziz H ^e   El Sayed, El Sayed M ^e   Pfeilschifter, Josef ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e AL AZHAR UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; CXCL16 CHEMOKINE; GAMMA INTERFERON; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN ADAM 10; SCAVENGER RECEPTOR; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GLOMERULOPATHY; HUMAN; HUMAN CELL; KIDNEY BIOPSY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 67049125674     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080960     Document Type: Article

References (57)

1. Mundel P, Kriz W: Structure and function of podocytes: an update. Anat Embryol (Berl) 1995, 192:385-397
2. Asanuma K, Yanagida-Asanuma E, Takagi M, Kodama F, Tomino Y: The role of podocytes in proteinuria. Nephrology (Carlton) 2007, 12(Suppl 3):S15-S20 (Pubitemid 350077387)
3. Wiggins RC: The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 2007, 71:1205-1214 (Pubitemid 46884251)
4. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F: Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996, 334:878-883 (Pubitemid 26107345)
5. Rossi D, Zlotnik A: The biology of chemokines and their receptors. Annu Rev Immunol 2000, 18:217-242 (Pubitemid 30365380)
6. Ludwig A, Weber C: Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb Haemost 2007, 97:694-703
7. Hofnagel O, Luechtenborg B, Plenz G, Robenek H: Expression of the novel scavenger receptor SR-PSOX in cultured aortic smooth muscle cells and umbilical endothelial cells. Arterioscler Thromb Vasc Biol 2002, 22:710-711 (Pubitemid 34408758)
8. Matloubian M, David A, Engel S, Ryan JE, Cyster JG: A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 2000, 1:298-304
9. Shashkin P, Simpson D, Mishin V, Chesnutt B, Ley K: Expression of CXCL16 in human T cells. Arterioscler Thromb Vasc Biol 2003, 23:148-149 (Pubitemid 36091640)
10. Shimaoka T, Kume N, Minami M, Hayashida K, Kataoka H, Kita T, Yonehara S: Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem 2000, 275:40663-40666 (Pubitemid 32054881)
11. Wilbanks A, Zondlo SC, Murphy K, Mak S, Soler D, Langdon P, Andrew DP, Wu L, Briskin M: Expression cloning of the STRL33/ BONZO/TYMSTR ligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol 2001, 166:5145-5154 (Pubitemid 32280729)
12. Heydtmann M, Lalor PF, Eksteen JA, Hubscher SG, Briskin M, Adams DH: CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol 2005, 174:1055-1062 (Pubitemid 40094302)
13. Shimaoka T, Nakayama T, Fukumoto N, Kume N, Takahashi S, Yamaguchi J, Minami M, Hayashida K, Kita T, Ohsumi J, Yoshie O, Yonehara S: Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J Leukoc Biol 2004, 75:267-274 (Pubitemid 38174584)
14. Minami M, Kume N, Shimaoka T, Kataoka H, Hayashida K, Akiyama Y, Nagata I, Ando K, Nobuyoshi M, Hanyuu M, Komeda M, Yonehara S, Kita T: Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2001, 21:1796-1800 (Pubitemid 34219784)
15. Shimaoka T, Nakayama T, Hieshima K, Kume N, Fukumoto N, Minami M, Hayashida K, Kita T, Yoshie O, Yonehara S: Chemokines generally exhibit scavenger receptor activity through their receptor-binding domain. J Biol Chem 2004, 279:26807-26810 (Pubitemid 38812513)
16. Abel S, Hundhausen C, Mentlein R, Schulte A, Berkhout TA, Broadway N, Hartmann D, Sedlacek R, Dietrich S, Muetze B, Schuster B, Kallen KJ, Saftig P, Rose-John S, Ludwig A: The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 2004, 172:6362-6372 (Pubitemid 38621245)
17. Gough PJ, Garton KJ, Wille PT, Rychlewski M, Dempsey PJ, Raines EW: A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol 2004, 172:3678-3685
18. Ludwig A, Hundhausen C, Lambert MH, Broadway N, Andrews RC, Bickett DM, Leesnitzer MA, Becherer JD: Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb Chem High Throughput Screen 2005, 8:161-171 (Pubitemid 40388743)
19. Geissmann F, Cameron TO, Sidobre S, Manlongat N, Kronenberg M, Briskin MJ, Dustin ML, Littman DR: Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol 2005, 3:e113 (Pubitemid 40721158)
20. Jiang X, Shimaoka T, Kojo S, Harada M, Watarai H, Wakao H, Ohkohchi N, Yonehara S, Taniguchi M, Seino K: Cutting edge: critical role of CXCL16/CXCR6 in NKT cell trafficking in allograft tolerance. J Immunol 2005, 175:2051-2055 (Pubitemid 41113808)
21. van d., V, van Lieshout AW, Toonen LW, Sloetjes AW, van den Berg WB, Figdor CG, Radstake TR, Adema GJ: Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints. Arthritis Rheum 2005, 52:1381-1391
22. Glassock RJ: Diagnosis and natural course of membranous nephropathy. Semin Nephrol 2003, 23:324-332 (Pubitemid 37022035)
23. Schramme A, Abdel-Bakky MS, Gutwein P, Obermuller N, Baer PC, Hauser IA, Ludwig A, Gauer S, Schafer L, Sobkowiak E, Altevogt P, Koziolek M, Kiss E, Grone HJ, Tikkanen R, Goren I, Radeke H, Pfeilschifter J: Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney. Kidney Int 2008, 74:328-338 (Pubitemid 352001245)
24. Wu T, Xie C, Wang HW, Zhou XJ, Schwartz N, Calixto S, Mackay M, Aranow C, Putterman C, Mohan C: Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol 2007, 179:7166-7175
25. Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, Xing CY, Ni L, Mathieson PW, Mundel P: A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 2002, 13:630-638 (Pubitemid 34183927)
26. Wiechen K, Sers C, Agoulnik A, Arlt K, Dietel M, Schlag PM, Schneider U: Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am J Pathol 2001, 158:833-839 (Pubitemid 32221776)
27. Gutwein P, Schramme A, Sinke N, Abdel-Bakky MS, Voss B, Obermuller N, Doberstein K, Koziolek M, Fritzsche F, Johannsen M, Jung K, Schaider H, Altevogt P, Ludwig A, Pfeilschifter J, Kristiansen G: Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur J Cancer 2009, 45:478-489
28. Mundlos S, Pelletier J, Darveau A, Bachmann M, Winterpacht A, Zabel B: Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues. Development 1993, 119:1329-1341 (Pubitemid 23358597)
29. Bosmans JL, Holvoet P, Dauwe SE, Ysebaert DK, Chapelle T, Jurgens A, Kovacic V, Van Marck EA, De Broe ME, Verpooten GA: Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 1 1/2 years. Kidney Int 2001, 59:2346-2356 (Pubitemid 32467629)
30. Forbes JM, Coughlan MT, Cooper ME: Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008, 57:1446-1454
31. Stocker R, Keaney JF Jr: Role of oxidative modifications in atherosclerosis. Physiol Rev 2004, 84:1381-1478 (Pubitemid 39302636)
32. Tsimikas S: Oxidized low-density lipoprotein biomarkers in atherosclerosis. Curr Atheroscler Rep 2006, 8:55-61 (Pubitemid 43675755)
33. Singbartl K, Ley K: Leukocyte recruitment and acute renal failure. J Mol Med 2004, 82:91-101 (Pubitemid 38299708)
34. Tabata S, Kadowaki N, Kitawaki T, Shimaoka T, Yonehara S, Yoshie O, Uchiyama T: Distribution and kinetics of SR-PSOX/CXCL16 and CXCR6 expression on human dendritic cell subsets and CD4+ T cells. J Leukoc Biol 2005, 77:777-786 (Pubitemid 40628758)
35. Nanki T, Shimaoka T, Hayashida K, Taniguchi K, Yonehara S, Miyasaka N: Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis Rheum 2005, 52:3004-3014 (Pubitemid 41447079)
36. Ponticelli C: Membranous nephropathy. J Nephrol 2007, 20:268-287 (Pubitemid 47570357)
37. Segerer S, Nelson PJ, Schlondorff D: Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000, 11:152-176 (Pubitemid 30020438)
38. Charo IF, Ransohoff RM: The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006, 354:610-621
39. Hojo S, Koizumi K, Tsuneyama K, Arita Y, Cui Z, Shinohara K, Minami T, Hashimoto I, Nakayama T, Sakurai H, Takano Y, Yoshie O, Tsukada K, Saiki I: High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 2007, 67:4725-4731 (Pubitemid 46910179)
40. Ludwig A, Schulte A, Schnack C, Hundhausen C, Reiss K, Brodway N, Held-Feindt J, Mentlein R: Enhanced expression and shedding of the transmembrane chemokine CXCL16 by reactive astrocytes and glioma cells. J Neurochem 2005, 93:1293-1303 (Pubitemid 40776582)
41. Scholz F, Schulte A, Adamski F, Hundhausen C, Mittag J, Schwarz A, Kruse ML, Proksch E, Ludwig A: Constitutive expression and regulated release of the transmembrane chemokine CXCL16 in human and murine skin. J Invest Dermatol 2007, 127:1444-1455 (Pubitemid 46763000)
42. Hundhausen C, Schulte A, Schulz B, Andrzejewski MG, Schwarz N, von Hundelshausen P, Winter U, Paliga K, Reiss K, Saftig P, Weber C, Ludwig A: Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. J Immunol 2007, 178:8064-8072 (Pubitemid 46898078)
43. Okamura DM, Lopez-Guisa JM, Koelsch K, Collins S, Eddy AA: Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury. Am J Physiol Renal Physiol 2007, 293:F575-F585 (Pubitemid 47358129)
44. Postea O, Koenen RR, Hristov M, Weber C, Ludwig A: Homocysteine upregulates vascular transmembrane chemokine CXCL16 and induces CXCR6(+) lymphocyte recruitment in vitro and in vivo. J Cell Mol Med 2008, 12:1700-1709
45. Galle J, Heermeier K, Wanner C: Atherogenic lipoproteins, oxidative stress, and cell death. Kidney Int Suppl 1999, 71:S62-S65 (Pubitemid 29304816)
46. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL: Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000, 105:1049-1056 (Pubitemid 30217689)
47. Whitman SC, Rateri DL, Szilvassy SJ, Cornicelli JA, Daugherty A: Macrophage-specific expression of class A scavenger receptors in LDL receptor(-/-) mice decreases atherosclerosis and changes spleen morphology. J Lipid Res 2002, 43:1201-1208 (Pubitemid 34988168)
48. Yoshimi N, Ikura Y, Sugama Y, Kayo S, Ohsawa M, Yamamoto S, Inoue Y, Hirata K, Itabe H, Yoshikawa J, Ueda M: Oxidized phosphatidylcholine in alveolar macrophages in idiopathic interstitial pneumonias. Lung 2005, 183:109-121 (Pubitemid 41264740)
49. Bussolati B, Deregibus MC, Fonsato V, Doublier S, Spatola T, Procida S, Di Carlo F, Camussi G: Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/ AKT-signaling pathway. J Am Soc Nephrol 2005, 16:1936-1947 (Pubitemid 41716424)
50. Garcia GE, Truong LD, Li P, Zhang P, Johnson RJ, Wilson CB, Feng L: Inhibition of CXCL16 attenuates inflammatory and progressive phases of anti-glomerular basement membrane antibody-associated glomerulonephritis. Am J Pathol 2007, 170:1485-1496 (Pubitemid 47339295)
51. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F: Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 2005, 11:867-874 (Pubitemid 41161119)
52. Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel P: Cytokine dysregulation in chronic kidney disease: how can we treat it? Blood Purif 2008, 26:291-299
53. Holdsworth SR, Kitching AR, Tipping PG: Chemokines as therapeutic targets in renal disease. Curr Opin Nephrol Hypertens 2000, 9:505-511 (Pubitemid 30677028)
54. Wasserstein AG: Membranous glomerulonephritis. J Am Soc Nephrol 1997, 8:664-674 (Pubitemid 27496550)
55. Imai H, Hamai K, Komatsuda A, Ohtani H, Miura AB: IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int 1997, 51:270-276 (Pubitemid 27064546)
56. Noel LH, Aucouturier P, Monteiro RC., Preud'homme JL, Lesavre P: Glomerular and serum immunoglobulin G subclasses in membranous nephropathy and anti-glomerular basement membrane nephritis. Clin Immunol Immunopathol 1988, 46:186-194
57. Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O: Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol 2003, 170:1136-1140 (Pubitemid 36139476)